Ozmeriç Nurdan, Baydar Terken, Bodur Ayen, Engin Ayse Basak, Uraz Ahu, Eren Kaya, Sahin Gonul
Department of Periodontology, Faculty of Dentistry, Gazi University, Ankara, Turkey.
J Periodontol. 2002 Jul;73(7):720-5. doi: 10.1902/jop.2002.73.7.720.
Neopterin, a marker of cellular immune activation, is produced by human macrophages after induction by interferon gamma that is secreted by T lymphocytes. Neopterin concentrations in diverse body fluids have been reported to increase in parallel with bacteria in the clinical course of infections. Therefore, determination of neopterin in body fluids was thought to be useful for predicting the prognosis and diagnosis of aggressive forms of periodontal disease, in which the cell-mediated immune response plays an important role in immunopathogenesis. The aim of the present study was to observe the role of neopterin in the pathogenesis of aggressive periodontitis (AgP).
Thirteen individuals who were systemically and periodontally healthy and 16 systemically healthy individuals diagnosed with AgP were recruited for this study. Mixed saliva and urine samples were collected from each subject. Gingival crevicular fluid (GCF) samples were obtained from 6 teeth with > or =5 mm probing depth (PD). After evaluation of GCF amount from paper strips, enzyme-linked immunosorbent assay (ELISA) was employed to determine the amount of neopterin in urine, saliva, and GCF.
The amount of neopterin in urine and saliva measured 235.77+/-405.31 micromol neopterin/mol creatinine and 9.85+/-7.66 nmol/l, respectively, for the AgP group and 225.45+/-100.72 micromol neopterin/mol creatinine and 5.25+/-5.76 nmol/l, respectively, for controls. The present data demonstrate that, while salivary neopterin levels were found to be significantly different between periodontitis and control subjects, there were non-significant differences in urine neopterin levels. The amount and concentration of neopterin in GCF measured was 18+/-12.75 nmol/l and 3.67+/-2.40 nmol/ml for the AgP group and 2.51+/-1.72 nmol/l and 3.88+/-4.50 nmol/ml for the control group. When total amounts of neopterin are taken into consideration, a significant difference between AgP and controls is shown; however, no significant difference in net concentration of neopterin was found between both groups.
This study is the first report to evaluate the involvement of neopterin in AgP and this might be considered of value in understanding periodontal disease mechanisms.
新蝶呤是细胞免疫激活的标志物,由T淋巴细胞分泌的干扰素γ诱导后,由人类巨噬细胞产生。据报道,在感染的临床过程中,不同体液中的新蝶呤浓度与细菌数量平行增加。因此,测定体液中的新蝶呤被认为有助于预测侵袭性牙周炎的预后和诊断,在侵袭性牙周炎中,细胞介导的免疫反应在免疫发病机制中起重要作用。本研究的目的是观察新蝶呤在侵袭性牙周炎(AgP)发病机制中的作用。
本研究招募了13名全身和牙周健康的个体以及16名被诊断为AgP的全身健康个体。从每个受试者收集混合唾液和尿液样本。从6颗探诊深度(PD)≥5mm的牙齿获取龈沟液(GCF)样本。在通过纸条评估GCF量后,采用酶联免疫吸附测定(ELISA)法测定尿液、唾液和GCF中的新蝶呤量。
AgP组尿液和唾液中的新蝶呤量分别为235.77±405.31微摩尔新蝶呤/摩尔肌酐和9.85±7.66纳摩尔/升,对照组分别为225.45±100.72微摩尔新蝶呤/摩尔肌酐和5.25±5.76纳摩尔/升。目前的数据表明,虽然牙周炎患者和对照组之间唾液新蝶呤水平存在显著差异,但尿液新蝶呤水平无显著差异。AgP组GCF中新蝶呤的量和浓度分别为18±12.75纳摩尔/升和3.67±2.40纳摩尔/毫升,对照组分别为2.51±1.72纳摩尔/升和3.88±4.50纳摩尔/毫升。当考虑新蝶呤的总量时,AgP组与对照组之间存在显著差异;然而,两组之间新蝶呤的净浓度无显著差异。
本研究是评估新蝶呤参与AgP的首篇报道,这可能对理解牙周病机制具有价值。